TABLE 3.
Rate of major adverse event.
| References/ RCTs |
Myalgia | Liver dysfunction | Nausea | Vomiting | Decreased appetite | |
| (17) | Statins + SSRIs group | 0/34 | 0/34 | 16/34 | 4/34 | 1/34 |
| SSRIs group | 0/34 | 0/34 | 16/34 | 4/34 | 8/34 | |
| (18) | Statins + SSRIs group | 0/30 | NR | NR | NR | NR |
| SSRIs group | 0/30 | NR | NR | NR | NR | |
| (19) | Statins + SSRIs group | 9/44§ | 0/22 | 9/44§ | ||
| SSRIs group | 0/22 | |||||
| (20) | Statins + SSRIs group | 0/23 | 0/23 | 0/23 | 0/23 | 2/23 |
| SSRIs group | 0/23 | 0/23 | 0/23 | 0/23 | 0/23 | |
| (21) | Statins + SSRIs group | NR | NR | NR | NR | NR |
| SSRIs group | NR | NR | NR | NR | NR | |
| (22) | Statins + SSRIs group | 0/10 | 1/20# | NR | NR | NR |
| SSRIs group | 0/10 | NR | NR | NR | ||
| (23) | Statins + SSRIs group | 2/77 | NR | 5/77 | NR | 2/77 |
| SSRIs group | 0/73 | NR | 3/73 | NR | 0/73 | |
§, nine adverse event were reported in patients, including myalgia, increased appetite, decreased appetite, nausea, vomiting, headache, constipation, insomnia, and abdominal pain; #,one with asymptomatic mild elevation of hepatic enzymes; RCT, randomized controlled trial; SSRI, selective serotonin reuptake inhibitor.